Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback